{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:29:15Z","timestamp":1794324555729,"version":"4.9.0"},"reference-count":63,"publisher":"ScopeMed","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.medarch.org\/\/?sec=licenseinfo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.5455\/medarh.2019.73.404-407","type":"journal-article","created":{"date-parts":[[2019,12,25]],"date-time":"2019-12-25T17:48:36Z","timestamp":1577296116000},"source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Prophylactic Doses of Reviparin on the Postoperative Value of Platelets"],"prefix":"10.5455","member":"3407","reference":[{"key":"ref1","unstructured":"1.  Shih AW1,\u00a0Sheppard JI,\u00a0Warkentin TE. Platelet count recov -"},{"key":"ref2","unstructured":"ery and seroreversion in immune HIT despite continuation of"},{"key":"ref3","unstructured":"heparin: further observations and literature review. Thromb"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Haemost.\u00a02017 Oct 5; 117(10): 1868-1874. doi: 10.1160\/TH17-","DOI":"10.1160\/TH17-03-0212"},{"key":"ref5","unstructured":"2.  Fathi M. Heparin-induced thrombocytopenia (HIT): Identifi -"},{"key":"ref6","unstructured":"cation and treatment pathways. Glob Cardiol Sci Pract. 2018"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jun 30; 2018(2): 15. doi:\u00a010.21542\/gcsp.2018.15","DOI":"10.1016\/j.fopow.2018.09.006"},{"key":"ref8","unstructured":"3.\u00a0 Greinacher A. Clinical Practice. Heparin-induced thrombocy -"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"topenia.\u00a0N Engl J Med [Internet]\u00a02015; 373(3): 252-261.\u00a0Avail -","DOI":"10.1056\/NEJMcp1411910"},{"key":"ref10","unstructured":"able from:\u00a0http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26176382\u00a0."},{"key":"ref11","unstructured":"4.\u00a0 Linkins LA, Bates SM, Lee AYY, Heddle NM, Wang G,"},{"key":"ref12","unstructured":"Warkentin TE. Combination of 4Ts score and PF4\/H-PaGIA"},{"key":"ref13","unstructured":"for diagnosis and management of heparin-induced thrombo -"},{"key":"ref14","unstructured":"cytopenia: prospective cohort study.\u00a0Blood [Internet]\u00a02015;"},{"key":"ref15","unstructured":"126(5): 597-603.\u00a0Available from:\u00a0http:\/\/www.ncbi.nlm.nih."},{"key":"ref16","unstructured":"gov\/pubmed\/25926600\u00a0."},{"key":"ref17","unstructured":"5.  Palade R., N\u0103st\u0103sescu T, Voiculescu D. The importance of fors -"},{"key":"ref18","unstructured":"eeing and early diagnosis of thromboembolic disease. Chiru -"},{"key":"ref19","unstructured":"rgia (Bucur). 2004 Jan-Feb; 99(1): 43-48."},{"key":"ref20","unstructured":"6.  Del Bono R, Martini G, Volpi R., Update on low molecular"},{"key":"ref21","unstructured":"weight heparins at the beginning of third millennium. Focus on reviparin. Eur Rev Med Pharmacol Sci. 2011 Aug; 15(8):"},{"key":"ref22","unstructured":"7.  Junqueira DR1, Zorzela LM2, Perini EUnfractionated hepa -"},{"key":"ref23","unstructured":"rin versus low molecular weight heparins for avoiding hep -"},{"key":"ref24","unstructured":"arin-induced thrombocytopenia in postoperative patients."},{"key":"ref25","unstructured":"Cochrane Database Syst Rev. 2017 Apr 21; 4: CD007557. doi:"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"10.1002\/14651858.CD007557.","DOI":"10.1002\/14651858.CD007557"},{"key":"ref27","unstructured":"8.\u00a0 Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A."},{"key":"ref28","unstructured":"Fondaparinux for the treatment of suspected heparin-induced"},{"key":"ref29","unstructured":"thrombocytopenia: a propensity score-matched study.\u00a0Blood"},{"key":"ref30","unstructured":"[Internet]\u00a02015; 125(6): 924-929.\u00a0Available from:\u00a0http:\/\/www."},{"key":"ref31","unstructured":"bloodjournal.org\/cgi\/doi\/10.1182\/blood-2014-09-599498\u00a0."},{"key":"ref32","unstructured":"9.\u00a0 Cuker A. Management of the multiple phases of heparin-in -"},{"key":"ref33","unstructured":"duced thrombocytopenia.\u00a0Thromb Haemost.\u00a02016; 116(5):"},{"key":"ref34","unstructured":"10.\u00a0 Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Pre -"},{"key":"ref35","unstructured":"dictive value of the 4Ts scoring system for heparin-induced"},{"key":"ref36","unstructured":"thrombocytopenia: a systematic review and meta-analy -"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"sis.\u00a0Blood [Internet]\u00a02012; 120(20): 4160-4167.\u00a0Available","DOI":"10.1182\/blood-2012-07-443051"},{"key":"ref38","unstructured":"from:\u00a0http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22990018\u00a0."},{"key":"ref39","unstructured":"11.\u00a0 Cuker A, Cines DB. How I treat heparin-induced thrombo -"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"cytopenia.\u00a0Blood [Internet]\u00a02012; 119(10): 2209-2218.\u00a0Avail -","DOI":"10.1182\/blood-2011-11-376293"},{"key":"ref41","unstructured":"able from:\u00a0http:\/\/www.bloodjournal.org\/cgi\/doi\/10.1182\/"},{"key":"ref42","unstructured":"blood-2011-11-376293\u00a0."},{"key":"ref43","unstructured":"12.\u00a0 Linkins L-A, Dans AL, Moores LK, Bona R, Davidson BL,"},{"key":"ref44","unstructured":"Schulman S, et al. Treatment and prevention of heparin-in -"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"duced thrombocytopenia.\u00a0Chest [Internet]\u00a02012; 141(2): e495S-","DOI":"10.1378\/chest.11-2303"},{"key":"ref46","unstructured":"e530S.\u00a0 Available from:\u00a0 http:\/\/linkinghub.elsevier.com\/re -"},{"key":"ref47","unstructured":"trieve\/pii\/S0012369212601305."},{"key":"ref48","unstructured":"13.\u00a0 Warkentin TE, Sheppard J-AI, Chu FV, Kapoor A, Crowther"},{"key":"ref49","unstructured":"MA, Gangji A. Plasma exchange to remove HIT antibod -"},{"key":"ref50","unstructured":"ies: dissociation between enzyme-immunoassay and plate -"},{"key":"ref51","unstructured":"let activation test reactivities.\u00a0 Blood [Internet]\u00a0 2015;125(1):"},{"key":"ref52","unstructured":"195-198.\u00a0Available from:\u00a0http:\/\/www.bloodjournal.org\/cgi\/"},{"key":"ref53","unstructured":"doi\/10.1182\/blood-2014-07-590844"},{"key":"ref54","unstructured":"14.  Pavlovic S, Zivkovic S, Kora\u00e6evic G., Determination of factor"},{"key":"ref55","unstructured":"Xa inhibition doses of low-molecular heparin, nadroparin and"},{"key":"ref56","unstructured":"reviparin in urological patients. Vojnosanit Pregl. 2007 Aug;"},{"key":"ref57","unstructured":"64(8): 538-542."},{"key":"ref58","unstructured":"15.  White RH, Zhou H, Romano PS. Incidence of idiopathic deep"},{"key":"ref59","unstructured":"venous thrombosis and secondary thromboembolism among"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"ethnic groups in California. Ann Intern Med. 1998; 128: 737-7","DOI":"10.7326\/0003-4819-128-9-199805010-00006"},{"key":"ref61","unstructured":"16.  Wellington K, McClellan K, Jarvis B. Reviparin: a review of"},{"key":"ref62","unstructured":"its efficacy in the prevention and treatment of venous throm -"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"boembolism. Drugs. 2001; 61(8): 1185-1209.","DOI":"10.2165\/00003495-200161080-00017"}],"container-title":["Medical Archives"],"original-title":[],"link":[{"URL":"https:\/\/ejmanager.com\/mnstemps\/10\/10-1577180159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:56:16Z","timestamp":1791482176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejmanager.com\/mnstemps\/10\/10-1577180159.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":63,"URL":"https:\/\/doi.org\/10.5455\/medarh.2019.73.404-407","relation":{},"ISSN":["0350-199X"],"issn-type":[{"value":"0350-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}